Keywords: idec, begins, ph, iii, registration, trial, pharmaceuticals

IDEC Begins Ph III Registration Trial

Article | 04 March 1998

IDEC Pharmaceuticals has commenced a Phase III clinical trial of itsinvestigational radioimmunotherapy product IDEC-Y2B8 plus Rituxan (rituximab) in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Rituxan

Rituximab

Go to drug listing